Treatment Guide

What Antidepressant Is Best for Anxiety? Drug-by-Drug Evidence

No antidepressant is best for every anxiety disorder. A 2025 Cochrane review found venlafaxine, duloxetine and escitalopram cut GAD symptoms most consistently.

Mental Health Stats Research Team 7 min read

Key Takeaways

  • No single antidepressant is best for anxiety: in a 2025 Cochrane review of generalized anxiety disorder trials, venlafaxine, duloxetine and escitalopram showed the clearest symptom reductions over placebo[1].2025[1]
  • Antidepressants as a group raised the GAD response rate to 559 per 1,000 from 396 per 1,000 on placebo, across 20 trials with 7,267 participants[1].559 vs. 396[1]
  • For panic disorder, a 2022 BMJ review of 87 studies found sertraline and escitalopram combined high remission with a low risk of adverse events[2].87 studies[2]
  • Bupropion and the SSRIs produced similar anxiety improvement in a pooled analysis of 10 depression trials with 2,890 patients, but bupropion has little trial data in primary anxiety disorders[3][1].2,890 patients[3]
  • Side effects vary widely between antidepressants: sexual dysfunction rates ranged from 25.8% to 80.3% across the antidepressants that exceeded placebo in a 2009 meta-analysis[4].25.8% to 80.3%[4]
How these comparisons are measured: Most anxiety drug trials score symptoms on the clinician-rated Hamilton Anxiety Rating Scale (HAM-A), and most GAD trials ran 12 weeks or less[1]. Nearly all of the evidence compares each drug with placebo rather than with other antidepressants, so differences between drugs are indirect. This guide reports what trials found and is not a guide to starting, switching or stopping a medication.

What Antidepressant Is Best for Anxiety? What the Trials Show

There is no single-drug answer to what antidepressant is best for anxiety. In the 2025 Cochrane review of placebo-controlled trials in generalized anxiety disorder (GAD), the SNRIs venlafaxine and duloxetine and the SSRI escitalopram showed the most consistent drops in symptom scores, while others, such as vortioxetine and vilazodone, were tested in only one trial each[1].

Antidepressants are medications used to treat depression, and NIMH notes that SSRIs and SNRIs are also used to treat anxiety disorders[5]. For panic disorder and social anxiety disorder, prescribers typically start with SSRIs or other antidepressants because they have fewer side effects than other medications[5].

The answer shifts with the type of anxiety disorder and with side effects, which vary widely from one antidepressant to another. This guide compares antidepressants drug by drug; how they stack up against benzodiazepines, pregabalin and buspirone is covered in what is the best medicine for anxiety, and SSRI-only details are in SSRI for anxiety.

The largest network analysis for GAD, published in The Lancet in 2019, pooled 89 trials with 25,441 patients and found duloxetine, venlafaxine and escitalopram more efficacious than placebo with relatively good acceptability[6]. Mirtazapine, sertraline, fluoxetine and agomelatine also looked efficacious and well tolerated, but the authors noted those findings were limited by small sample sizes[6].

How Individual Antidepressants Performed in GAD Trials

AntidepressantClassHAM-A change vs. placeboTrials (participants)Total dropouts vs. placebo
VenlafaxineSNRI-3.1112 (3,498)Similar
DuloxetineSNRI-3.036 (2,070)Similar
EscitalopramSSRI-2.586 (1,908)Similar
SertralineSSRI-2.00 (NS)3 (736)Similar
ParoxetineSSRI-1.717 (2,183)Higher
VilazodoneOther-1.30 (NS)1 (395)Similar
ImipramineTCA-3.90 (NS)1 (28)No data

Mean difference in HAM-A score change versus placebo for adults with GAD, by antidepressant; more negative means larger improvement[1].

1NS = not statistically different from placebo. Imipramine's estimate comes from a single 28-person trial[1].

2Dropout comparisons are total discontinuations for any reason; paroxetine had more dropouts than placebo (risk ratio 1.25 across 7 trials)[1].

Sources

  • •Cochrane Database of Systematic Reviews, 2025

Treatment response (in anxiety drug trials)

The share of trial participants whose symptoms improve by a preset margin, most often a reduction of at least 50% on the Hamilton Anxiety Rating Scale (HAM-A)[1]. Some trials instead count a Clinical Global Impression of Improvement score of 1 or 2, meaning "very much" or "much" improved[1].

Related Terms

HAM-A
remission
mean difference
placebo response

Source: Cochrane Database of Systematic Reviews, 2025

SSRI or SNRI: Does the Antidepressant Class Matter?

Both first-line classes beat placebo in GAD, and the SNRIs posted somewhat larger average gains. In the 2025 Cochrane review, SNRIs reduced HAM-A scores by 3.04 points more than placebo across 16 trials, compared with 2.22 points for SSRIs across 15 trials[1].

Response rates followed the same pattern, with risk ratios of 1.41 for SNRIs and 1.31 for SSRIs when response was defined by study authors[1]. These are separate comparisons with placebo, not head-to-head trials, so they do not prove one class is better.

Total dropout rates for both classes were no different from placebo (risk ratio 1.06 for SSRIs and 1.03 for SNRIs), and both raised the share of people reporting any adverse effect by a similar margin (1.16 and 1.14)[1].

FDA approvals differ by drug. Venlafaxine extended-release is approved for GAD, social anxiety disorder and panic disorder in adults[7]. Duloxetine is approved for GAD, with efficacy established in patients 7 to 17 years old as well as adults[8].

Citalopram, another SSRI, is approved only for major depressive disorder in adults[9]. Approvals for escitalopram, sertraline, paroxetine and fluoxetine are listed in SSRI for anxiety.

Which Antidepressant Is Best for Panic Disorder and Social Anxiety?

Panic disorder

In a 2022 BMJ network meta-analysis of 87 studies and 12,800 participants with panic disorder, tricyclics, MAOIs, SSRIs and SNRIs all produced higher remission rates than placebo[2]. Among individual SSRIs, sertraline and escitalopram were associated with high remission and a low risk of adverse events[2].

The authors ranked SNRIs below SSRIs for both remission and adverse events and described them as a possible second-line option[2]. They judged the evidence too thin to support mirtazapine-type antidepressants (NaSSAs), citing high rates of drowsiness and weight gain[2].

Almost all of the studies (86 of 87) had some concern or a high risk of bias, so the rankings rest on moderate- to very-low-certainty evidence[2].

Social anxiety disorder

A 2017 Cochrane review of social anxiety disorder pooled 24 SSRI trials with 4,984 participants and found a treatment response risk ratio of 1.65 versus placebo, based on very-low-quality evidence[10]. SSRIs were the only medication class shown to reduce relapse, based on moderate-quality evidence[10].

The older MAOI class showed a larger response ratio (2.36), but it came from 4 trials with 235 people and was rated low quality[10]. Venlafaxine, an SNRI, also reduced symptom severity in that review, though most of the evidence was very low quality[10].

Antidepressant Classes in Panic Disorder Trials

Drug classRemission vs. placebo (risk ratio)Adverse events vs. placebo (risk ratio)
Tricyclic antidepressants1.391.79
SSRIs1.381.19
MAOIs1.30Not significantly different
SNRIs1.27Higher
Benzodiazepines (comparison)1.471.76

Network meta-analysis of 87 randomized trials in adults with panic disorder, with or without agoraphobia[2].

1A risk ratio above one means more remissions or more adverse events than placebo.

2Benzodiazepines are not antidepressants and are shown for comparison; MAOIs were superior to placebo for remission but not different from placebo on other outcomes[2].

Sources

  • •BMJ, 2022

Antidepressants With Weaker or Mixed Anxiety Evidence

Some widely prescribed antidepressants have little support in primary anxiety disorders. In the Cochrane GAD review, vortioxetine was no better than placebo on treatment response (risk ratio 1.04, 1 trial, 610 participants)[1].

Vilazodone improved response in its single GAD trial (risk ratio 1.25, 395 participants) but did not separate from placebo on symptom scores[1]. Agomelatine raised response (risk ratio 1.93 across 3 trials and 773 participants), with moderate-to-substantial heterogeneity between studies[1].

Bupropion

The Cochrane GAD review found no trial data for bupropion's class (NDRIs) on its main outcome[1]. The evidence that exists comes from depression: pooling 10 randomized trials with 2,890 patients with major depressive disorder, bupropion and the SSRIs improved HAM-A anxiety scores by similar amounts (8.8 vs. 9.1 points)[3].

That analysis also found no consistent difference in how quickly anxiety eased, and its authors wrote that, contrary to clinician impression, bupropion and the SSRIs did not appear to differ in anxiolytic efficacy in depression[3]. Whether that holds for GAD, panic disorder or social anxiety without depression has not been well tested.

Mirtazapine, tricyclics and MAOIs

Mirtazapine looked efficacious and well tolerated for GAD in the 2019 Lancet analysis, but on small samples[6]. Tricyclics were effective for panic disorder yet raised adverse events by 79% over placebo, and the BMJ authors noted MAOIs carry a risk of hypertensive crisis and multiple drug interactions[2].

Comparisons for treating anxiety alongside depression are in what is the best drug for depression and anxiety.

Number of people with GAD who needed antidepressant treatment for one additional person to respond, compared with placebo
7

Pooled from 20 placebo-controlled trials with 7,267 participants, rated high-certainty evidence. Response meant at least a 50% drop on the HAM-A, and 559 of every 1,000 people on an antidepressant responded versus 396 of every 1,000 on placebo.

"seven people need to be treated for one more person to experience a response to treatment"

Cochrane Database of Systematic Reviews(2025) View Source

Side Effects That Separate One Antidepressant From Another

Across GAD trials, antidepressants roughly doubled the rate of dropping out because of side effects (risk ratio 2.18), equal to one extra dropout for every 17 people treated[1]. Sleepiness or drowsiness was 2.3 times as common as on placebo, with similar ratios for paroxetine (2.33) and venlafaxine (2.20)[1].

Sexual side effects

A 2009 meta-analysis found sexual dysfunction significantly above placebo for sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram and fluvoxamine, listed in decreasing order of impact, with rates from 25.8% to 80.3% of patients[4]. Bupropion, mirtazapine, agomelatine and nefazodone did not differ significantly from placebo[4].

Discontinuation symptoms

A 2024 Lancet Psychiatry meta-analysis of 79 studies and 21,002 patients found at least one discontinuation symptom in 31% of people stopping an antidepressant and 17% of people stopping placebo[11]. Desvenlafaxine, venlafaxine, imipramine and escitalopram were associated with more frequent symptoms, and imipramine, paroxetine and desvenlafaxine or venlafaxine with more severe ones[11].

Heart rhythm and dose limits

Citalopram's label warns of dose-dependent QTc prolongation and sets its maximum dose at 40 mg a day, or 20 mg a day for people over 60, people with hepatic impairment and CYP2C19 poor metabolizers[9].

Side-Effect Differences Among Antidepressants

Side effectAntidepressants with more of itLower or no difference from placebo
Sexual dysfunctionSertraline, venlafaxine, citalopram, paroxetine, fluoxetineBupropion, mirtazapine, agomelatine, nefazodone (no difference from placebo)
Discontinuation symptoms, frequencyDesvenlafaxine, venlafaxine, imipramine, escitalopramNot ranked
Discontinuation symptoms, severityImipramine, paroxetine, desvenlafaxine or venlafaxineNot ranked
Sleepiness in GAD trialsParoxetine, venlafaxineSertraline: no difference (1 trial, 42 people)
Drowsiness and weight gain in panic trialsNaSSAs such as mirtazapineNot ranked

Side effects that differ between individual antidepressants, from meta-analyses[4][11][1][2].

1Sexual dysfunction rates came from studies that asked about sexual function directly; the 'more' list shows the five highest-impact drugs of the ten that exceeded placebo.

2Citalopram also carries a 40 mg daily dose cap because of QTc prolongation[9].

Sources

  • •Journal of Clinical Psychopharmacology, 2009
  • •The Lancet Psychiatry, 2024
  • •Cochrane, 2025
  • •BMJ, 2022
  • •FDA, 2022

How Long an Antidepressant Takes to Work for Anxiety

NIMH says antidepressants usually take 4 to 8 weeks to work, and that sleep, appetite, energy and concentration often improve before mood lifts[5]. The Cochrane authors add that a full response can take up to 12 weeks, while most GAD trials ran 12 weeks or less[1].

Longer relapse-prevention studies of duloxetine, escitalopram, vortioxetine, paroxetine and venlafaxine found lower relapse rates in people who kept taking the drug for at least six months after an initial open-label treatment period[1]. The 2019 Lancet authors concluded that the failure of a first drug might not be a reason to abandon medication, since several classes work[6].

NIMH notes that children, teenagers and young adults under 25 may have an increase in suicidal thoughts or behavior on antidepressants, especially in the first weeks or after a dose change[5]. How many Americans take antidepressants is tracked in antidepressant usage statistics.

Frequently Asked Questions

Sources & References

  1. Kopcalic K, Arcaro J, Pinto A, et al. Antidepressants versus placebo for generalised anxiety disorder (GAD). Cochrane Database of Systematic Reviews. Published 2025. Accessed October 2026. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012942.pub2/full [Link]
  2. Chawla N, Anothaisintawee T, Charoenrungrueangchai K, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. Published 2022. Accessed October 2026. https://www.bmj.com/content/376/bmj-2021-066084 [Link]
  3. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. Journal of Psychiatric Research. Published 2008. Accessed October 2026. https://doi.org/10.1016/j.jpsychires.2007.05.012 [Link]
  4. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of Clinical Psychopharmacology. Published 2009. Accessed October 2026. https://doi.org/10.1097/JCP.0b013e3181a5233f [Link]
  5. National Institute of Mental Health. Mental Health Medications. National Institute of Mental Health. Published 2023. Accessed October 2026. https://www.nimh.nih.gov/health/topics/mental-health-medications [Link]
  6. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet. Published 2019. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31793-8/fulltext [Link]
  7. Effexor XR (venlafaxine extended-release) capsules: prescribing information. U.S. Food and Drug Administration. Published 2023. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf [Link]
  8. Cymbalta (duloxetine delayed-release capsules): prescribing information. U.S. Food and Drug Administration. Published 2019. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021427s051lbl.pdf [Link]
  9. Celexa (citalopram) tablets: prescribing information. U.S. Food and Drug Administration. Published 2022. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf [Link]
  10. Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database of Systematic Reviews. Published 2017. Accessed October 2026. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001206.pub3/full [Link]
  11. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry. Published 2024. Accessed October 2026. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(24)00133-0/fulltext [Link]

Related Statistics